Ronald Martell

Ronald Martell has a diverse work experience in the biopharmaceutical industry. Ronald is currently the CEO and President of Jasper Therapeutics since March 2022. Prior to that, they were the Director of MorphImmune, where they worked on advancing a specific targeting technology for reprogramming the immune system. Ronald was also the Co-founder and Executive Chairman of Indapta Therapeutics, Co-founder of Encellin, and Co-founder and Advisor of Orca Bio. Ronald served as the Executive Director of HAVAH Therapeutics, where they focused on women's hormonal health and the prevention of breast cancer with combination therapy. Additionally, they held the position of Chairman at Cetya Pharmaceuticals, Colorado State University, and Dana Farber Cancer Institute. Ronald has also worked as the President and CEO of Nuvelution Pharmaceuticals and as an Advisor at Keck School of Medicine of the University of Southern California. Ronald has served as a Director at PLUS THERAPEUTICS as well. These positions showcase their extensive experience and leadership in the biopharmaceutical field.

Ronald Martell attended The University of Akron from 1982 to 1986. However, the information does not mention the degree or field of study they pursued during this time.